Stress oxydant et thérapeutiques anti-tumorales (4) - Hugues de Thé (2025-2026)

The lecture provides a comprehensive and nuanced overview of anthracycline mechanisms, challenging the traditional topoisomerase-centric view. Professor de Thé presents both classical and recent findings, including his own research, with appropriate caveats. The scientific rigor is high, as he clearly distinguishes between established facts and hypotheses. The use of experimental data, such as the lack of DNA damage with clarubicine and the protective effect of antioxidants, strengthens the argument. The sources cited are primarily from peer-reviewed literature, though specific references are not always given in the lecture. The title accurately reflects the content, and the lecture is well-structured. However, the technical level is high, assuming prior knowledge of molecular biology. The discussion of ferroptosis is integrated but could be more detailed. Overall, this is an excellent lecture for an advanced audience, providing valuable insights into the mechanisms of action of anthracyclines and their relationship to oxidative stress.

The title accurately reflects the content, focusing on oxidative stress and anti-tumor therapies, with a specific case study on ferroptosis.

9/10

Lecture by a renowned professor at Collège de France, based on published research and his own work. High scientific rigor, clear presentation of data and limitations.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 00:00Introduction: recap of previous lecture on alkylating agents and oxidative stress.
• 02:00Introduction of anthracyclines and their classical mechanisms: topoisomerase II inhibition, DNA intercalation, and oxidative stress.
• 05:00Discussion of the limitations of the classical model: anthracyclines are more potent than pure topoisomerase inhibitors, and there are synergies.
• 10:00Presentation of clarubicine, an anthracycline used in East Asia, with fewer side effects (no cardiotoxicity, no sterility).
• 15:00Experimental data showing that clarubicine does not induce DNA damage, unlike doxorubicine and topoisomerase inhibitors.
• 20:00In vivo mouse models: clarubicine does not accelerate tumor development in p53 heterozygous mice, unlike doxorubicine.
• 25:00Cardiotoxicity: doxorubicine induces heart failure, while clarubicine does not.
• 30:00Chromatin remodeling: both doxorubicine and clarubicine cause histone release due to intercalation, leading to replicative stress.
• 35:00Link to oxidative stress: clarubicine-induced cell death is blocked by antioxidants (NAC, vitamin E).
• 40:00Discussion of mitochondrial effects and potential role of ferroptosis.

• Collège de France - Hugues de Thé chair — Official page for the professor's chair, providing context for the lecture series.
• Collège de France - Course agenda — Link to the course series on exploring therapeutic response in vivo.
• Collège de France - YouTube playlist — Playlist of all lectures by Hugues de Thé.

• Collège de France - Official website — Institutional source confirming the lecture's origin and academic context.

• www.fondation-cdf.fr
• fr.linkedin.com
• www.threads.net